Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Tutorial
April 9, 2026
OncoToolkit Team

IMDC (Heng) Risk Criteria for Metastatic Renal Cell Carcinoma — Calculator & Guide

Calculate IMDC/Heng risk score for metastatic renal cell carcinoma. Six prognostic factors determine favourable, intermediate, or poor risk to guide first-line systemic therapy selection.

Evidence-Based Guide

The IMDC (International Metastatic RCC Database Consortium) criteria, also known as the Heng criteria, are a validated prognostic model for metastatic renal cell carcinoma (mRCC). Six adverse factors — KPS <80%, time from diagnosis to treatment <1 year, haemoglobin below normal, corrected calcium above normal, neutrophils above normal, and platelets above normal — stratify patients into favourable (0 factors), intermediate (1–2 factors), or poor risk (3–6 factors) groups. This guide explains the criteria, compares IMDC with the older MSKCC model, and outlines how risk group assignment drives first-line treatment selection.

What Are the IMDC / Heng Criteria?

The IMDC risk model was developed by Daniel Heng and colleagues at the Tom Baker Cancer Centre and published in the Journal of Clinical Oncology in 2009. The study validated the model in 645 patients with metastatic renal cell carcinoma treated with first-line VEGF-targeted therapy (sunitinib, sorafenib, or bevacizumab).

The IMDC criteria built upon the earlier MSKCC (Motzer) criteria, which were developed in 1999 during the cytokine therapy era. Heng's key contribution was re-validating and refining the prognostic model for the targeted therapy era, replacing LDH with neutrophil and platelet counts as more discriminating laboratory parameters.

Today, the IMDC criteria are the standard risk stratification used in:

IMDC risk classification determines first-line treatment selection, making accurate scoring essential for clinical decision-making. In the UK, NICE guideline NG85 (Renal cancer) uses the IMDC criteria for systemic therapy selection, recommending cabozantinib or nivolumab plus ipilimumab for intermediate and poor-risk patients, and sunitinib or pazopanib for favourable-risk patients.

The 6 IMDC Risk Factors

Each factor is scored as present (1 point) or absent (0 points). The total number of adverse factors determines the risk group.

| Risk Factor | Adverse If... | Points | |-------------|--------------|--------| | Karnofsky Performance Status (KPS) | <80% | 1 | | Time from diagnosis to systemic therapy | <1 year | 1 | | Haemoglobin | Below lower limit of normal | 1 | | Corrected calcium | Above upper limit of normal | 1 | | Neutrophils | Above upper limit of normal | 1 | | Platelets | Above upper limit of normal | 1 |

Clinical Notes on Factor Assessment

Key point: Use the IMDC (Heng) Risk Score Calculator on OncoToolkit for instant risk stratification with all six factors.

IMDC Risk Groups and Survival

| Risk Group | Risk Factors | Median OS | % of Patients | |------------|-------------|-----------|---------------| | Favourable | 0 | 43.2 months | ~25% | | Intermediate | 1–2 | 22.5 months | ~53% | | Poor | 3–6 | 7.8 months | ~22% |

These survival data are from the original 2009 publication and reflect outcomes with first-generation VEGF-targeted therapies. Modern immunotherapy combinations have significantly improved outcomes across all risk groups:

While absolute survival has improved, the relative prognostic discrimination of the IMDC model remains valid — favourable-risk patients consistently outperform intermediate and poor-risk patients regardless of treatment era.

IMDC vs MSKCC (Motzer) Criteria — What's the Difference?

The MSKCC criteria (also called Motzer criteria) were developed in 1999 from patients treated with interferon-alpha — a cytokine therapy largely replaced by modern agents.

| Feature | MSKCC (Motzer) | IMDC (Heng) | |---------|---------------|-------------| | Year | 1999 | 2009 | | Treatment era | Cytokine therapy | Targeted therapy | | Number of factors | 5 | 6 | | Common factors | KPS, time to treatment, Hb, calcium | KPS, time to treatment, Hb, calcium | | Unique factors | LDH elevated | Neutrophils elevated, platelets elevated | | Validation cohort | Interferon-alpha | Sunitinib, sorafenib, bevacizumab | | Current use | Historical / legacy trials | Standard of care |

Why IMDC Replaced MSKCC

The IMDC model replaced LDH — which has limited specificity — with neutrophil and platelet counts, both of which reflect tumour-associated inflammation and have stronger independent prognostic value in the targeted therapy setting. The IMDC criteria were subsequently validated in multiple independent cohorts and across treatment lines, establishing them as the current standard.

The MSKCC criteria remain referenced in older literature and some ongoing trials stratified by MSKCC risk. OncoToolkit provides both calculators for clinical reference:

How IMDC Risk Guides Treatment in 2026

IMDC risk classification is now the primary determinant of first-line systemic therapy selection for metastatic RCC per NCCN and ESMO guidelines.

Favourable Risk (0 factors)

Favourable-risk patients derive less benefit from dual checkpoint inhibitor therapy (nivolumab + ipilimumab) compared with IO/TKI combinations, based on subgroup analyses from CheckMate 214.

Intermediate and Poor Risk (1–6 factors)

Dual immunotherapy (nivolumab + ipilimumab) showed the strongest overall survival benefit in intermediate/poor-risk patients, with a 4-year OS rate of 50% versus 39% with sunitinib in CheckMate 214.

Important note: Treatment recommendations evolve as new trial data emerge. Always consult current NCCN or ESMO guidelines and multidisciplinary tumour board recommendations for individual patient treatment planning.

Frequently Asked Questions

What is the Heng criteria for kidney cancer?

The Heng criteria (IMDC criteria) are a prognostic scoring system for metastatic renal cell carcinoma developed by Daniel Heng in 2009. Six adverse factors are evaluated: KPS <80%, time from diagnosis to treatment <1 year, low haemoglobin, elevated corrected calcium, elevated neutrophils, and elevated platelets. The number of factors present determines risk group assignment — favourable (0), intermediate (1–2), or poor (3–6) — which directly guides first-line treatment selection.

What is the difference between IMDC and MSKCC criteria?

The MSKCC (Motzer) criteria were developed in 1999 from patients treated with cytokine therapy and use 5 factors including elevated LDH. The IMDC (Heng) criteria were developed in 2009 from patients treated with targeted therapy and use 6 factors, replacing LDH with neutrophil and platelet counts. IMDC criteria are the current standard of care, validated across multiple treatment eras including modern immunotherapy combinations.

How does IMDC risk affect treatment choice?

IMDC risk directly determines first-line systemic therapy per NCCN guidelines. Favourable-risk patients are typically treated with immunotherapy/TKI combinations such as pembrolizumab plus axitinib. Intermediate and poor-risk patients may receive dual immunotherapy (nivolumab plus ipilimumab) or alternative IO/TKI combinations, as these regimens showed superior outcomes in higher-risk disease across pivotal clinical trials.

What is favourable risk renal cell carcinoma?

Favourable-risk mRCC is defined by having zero IMDC adverse risk factors. These patients — approximately 25% of the metastatic RCC population — have the best prognosis, with historical median overall survival of 43 months and substantially longer survival with modern immunotherapy combinations. Despite the favourable prognosis, systemic therapy is still indicated for most patients with metastatic disease.

This article is intended for healthcare professionals. Prognostic scores provide population-level estimates and should be interpreted within the context of individual patient characteristics, available treatments, and multidisciplinary clinical judgment.